These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 17047044)

  • 1. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
    Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
    Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
    Biswas S; Chytil A; Washington K; Romero-Gallo J; Gorska AE; Wirth PS; Gautam S; Moses HL; Grady WM
    Cancer Res; 2004 Jul; 64(14):4687-92. PubMed ID: 15256431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor beta resistant cells.
    Biswas S; Trobridge P; Romero-Gallo J; Billheimer D; Myeroff LL; Willson JK; Markowitz SD; Grady WM
    Genes Chromosomes Cancer; 2008 Feb; 47(2):95-106. PubMed ID: 17985359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
    Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
    Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
    Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
    Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
    Lücke CD; Philpott A; Metcalfe JC; Thompson AM; Hughes-Davies L; Kemp PR; Hesketh R
    Cancer Res; 2001 Jan; 61(2):482-5. PubMed ID: 11212236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of TGF-β signaling and loss of PTEN cooperate to induce colon cancer in vivo.
    Yu M; Trobridge P; Wang Y; Kanngurn S; Morris SM; Knoblaugh S; Grady WM
    Oncogene; 2014 Mar; 33(12):1538-47. PubMed ID: 23604118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis.
    Kress E; Skah S; Sirakov M; Nadjar J; Gadot N; Scoazec JY; Samarut J; Plateroti M
    Gastroenterology; 2010 May; 138(5):1863-74. PubMed ID: 20114049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressing TGFβ signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer.
    Oshima H; Nakayama M; Han TS; Naoi K; Ju X; Maeda Y; Robine S; Tsuchiya K; Sato T; Sato H; Taketo MM; Oshima M
    Cancer Res; 2015 Feb; 75(4):766-76. PubMed ID: 25687406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.
    Janssen KP; Alberici P; Fsihi H; Gaspar C; Breukel C; Franken P; Rosty C; Abal M; El Marjou F; Smits R; Louvard D; Fodde R; Robine S
    Gastroenterology; 2006 Oct; 131(4):1096-109. PubMed ID: 17030180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
    Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
    Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway.
    Trobridge P; Knoblaugh S; Washington MK; Munoz NM; Tsuchiya KD; Rojas A; Song X; Ulrich CM; Sasazuki T; Shirasawa S; Grady WM
    Gastroenterology; 2009 May; 136(5):1680-8.e7. PubMed ID: 19208363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
    Labbé E; Lock L; Letamendia A; Gorska AE; Gryfe R; Gallinger S; Moses HL; Attisano L
    Cancer Res; 2007 Jan; 67(1):75-84. PubMed ID: 17210685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice.
    Musteanu M; Blaas L; Mair M; Schlederer M; Bilban M; Tauber S; Esterbauer H; Mueller M; Casanova E; Kenner L; Poli V; Eferl R
    Gastroenterology; 2010 Mar; 138(3):1003-11.e1-5. PubMed ID: 19962983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW; Douville K; Benbow U; Brinckerhoff CE; Memoli VA; Arrick BA
    Oncogene; 2002 Jan; 21(1):108-18. PubMed ID: 11791181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/+ mouse.
    Paoni NF; Feldman MW; Gutierrez LS; Ploplis VA; Castellino FJ
    Physiol Genomics; 2003 Nov; 15(3):228-35. PubMed ID: 13130079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
    Yoo YA; Kang MH; Kim JS; Oh SC
    Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.
    Engle SJ; Hoying JB; Boivin GP; Ormsby I; Gartside PS; Doetschman T
    Cancer Res; 1999 Jul; 59(14):3379-86. PubMed ID: 10416598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation.
    Miguchi M; Hinoi T; Shimomura M; Adachi T; Saito Y; Niitsu H; Kochi M; Sada H; Sotomaru Y; Ikenoue T; Shigeyasu K; Tanakaya K; Kitadai Y; Sentani K; Oue N; Yasui W; Ohdan H
    PLoS One; 2016; 11(11):e0166422. PubMed ID: 27835699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
    Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
    Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.